Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

Cbd oil effects on diabetes skin

C. S. Crippa Ana



  • C. S. Crippa Ana
  • Publicações ano 2014
  • Introduction
  • Ana Crippa's 12 research works with 14 citations and reads, including: Ana Crippa has expertise in Psychology and Engineering. Ana C S Crippa; [ ]. Full Remission after Switching to Purified Cannabidiol. José A. S. Crippa,1,* Ana C. S. Crippa,2 Jaime E. C. Hallak,1 Rocio Martín-Santos,1,3. Cannabidiol's anti-anxiety (Zuardi et al., , ; Crippa et al., . Crippa J. A., Zuardi A. W., Garrido G. E., Wichert-Ana L., Guarnieri R., Ferrari L., et al. . [ CrossRef]; Spielberger C. D., Gorsuch R. L., Lushene R. E. ().

    C. S. Crippa Ana

    The data obtained in the seven components and the total PSQI score are indicative of good sleep quality. Total PSQI scores greater than five suggest difficulties in at least two components or moderate difficulties in more than three components Buysse et al. The comparative analyses between CBD and placebo indicate that none of the parameters evaluated presented statistically significant changes. To check if this interaction could have potentially interfered with the results, we split the subjects, comparing the placebo and CBD groups separately in the two orders first placebo or CBD.

    Again, there was no difference between groups in the two situations. We found no significant differences in polysomnography results following the administration of CBD and placebo to healthy volunteers.

    Likewise, there were no statistically significant changes in the subjective and cognitive measures collected during the two nights of polysomnographic exams. Several parameters were recorded during polysomnography, considering that the essential tests for sleep staging are electroencephalogram, electrooculogram, and electromyogram. Given the lack of studies on the effect of CBD on human polysomnography-monitored sleep, other parameters were selected based on studies that tested the effect of other drugs in healthy volunteers Orr et al.

    When comparing our polysomnographic data with results from other studies that used placebo in healthy volunteers, similar findings were observed Buysse et al. No statistically significant changes were found between the three different time points in the four factors evaluated by the VAMS and, as well as in the STAI. These results suggest that none of the different moments of the exams were subjectively rated as anxiogenic, sedative, uncomfortable or as producing cognitive impairment.

    It should be noted here that, unlike other medications, the anxiolytic effect of CBD is only observed when given to subjects in obviously anxiogenic situations Zuardi et al. In the present study, we found no residual effects of CBD on cognitive or psychomotor functions compared to placebo, as measured by the Digit Symbol Substitution and Symbol Copying subscales of the WAIS, which have been described as sensitive measures of residual drug effects Garber et al.

    Although no previous study on sleep and CBD applied these specific measures, our findings are consistent with a study on multiple sclerosis that used the digits test to assess possible changes in disease status following the administration of CBD associated with THC, in which no significant change was recorded Vaney et al.

    It is known that lack of sleep can interfere with certain aspects of cognitive functioning, such as attentional levels Goel et al. However, the results of the present study did not show any significant impairment in either the reaction time or number of errors measured by the PVT, suggesting that the attention levels of the volunteers were preserved in the morning after the sleep assessment, regardless of the administration of CBD or placebo.

    Not having administered the PVT test before CBD and placebo administration does not significantly affect the conclusions once the study does not intend to assess the effect of CBD on baseline vigilance which would require comparison with baseline PVT results , but to rather evaluate if CBD may be safely administered to patients without affecting their vigilance state overall, such that the patients may safely conduct every-day tasks, like for example driving.

    Earlier preclinical studies have suggested that the therapeutic effects of CBD might depend on the presence of specific clinical conditions. As an example, Campos et al. Thus, the absence of changes in the sleep of healthy volunteers treated with CDB in our study should not be considered as a final indication that CBD could not have positive effects in patients with sleep disorders. It is known that a major problem of several medications used in the treatment of clinical anxiety and depression is their effect on sleep architecture.

    Long-term use of benzodiazepines may also cause reduction of SWS, loss of efficacy in the treatment of insomnia, alterations in electroencephalogram results during sleep Poyares et al. Likewise, selective serotonin reuptake inhibitors SSRIs and selective serotonin and norepinephrine reuptake inhibitors SNRIs may interfere with sleep architecture and decrease restorative sleep, leading to increased awakenings, reduced REM sleep, increased REM latency, as well as increased periodic limb movement during sleep Feige et al.

    Additionally, studies on the anxiolytic, antipsychotic and antiparkinson effects of CBD described no sedation or drowsiness side effects in their volunteers Zuardi et al.

    These findings complement the literature on the few significant side effects resulting from the administration of CBD to humans in a wide range of doses, administered chronically or acutely Bergamaschi et al. It seems, therefore, that CBD has an adequate safety profile with good tolerability and does not affect psychomotricity or cognition Hayakawa et al.

    The relative representativeness of the small sample size and the use of a single dose of CBD can perhaps be regarded as a limitation of our study, as it does not allow the assessment of the effects of chronic treatment with CBD on sleep.

    In the study by Chagas et al. Since the effects of CBD are biphasic Zuardi et al. Moreover, monitoring changes in sleep using a conventional polysomnography presents some intrinsic limitations, as it is insufficient alone to detect drug-induced changes of the sleep EEG.

    For this purpose, a spectral analysis or a similar procedure is also needed. Conversely, the use of preclinical polysomnography to characterize drug-induced sleep disturbances has been increasingly recommended in the regulatory context Authier et al. Finally, it is essential to evaluate the effects of CBD in a larger sample and in individuals diagnosed with sleep disorders in addition to healthy volunteers.

    Despite these limitations, this is the first controlled study to evaluate the effects of CBD on sleep architecture using polysomnography. Although the absence of interference with the sleep cycle is not sufficient for concluding that sleep is not affected, the results obtained contribute for the understanding of the effects of CBD in the modulation of sleep in humans. We found no differences between CBD and placebo in respect to polysomnographic findings or cognitive and subjective measures in a sample of healthy subjects.

    Unlike widely used anxiolytic and antidepressant drugs such as benzodiazepines and SSRIs, the acute administration of an anxiolytic dose of CBD does not appear to interfere with the sleep cycle of healthy volunteers. Future studies should address the effects of CBD on the sleep-wake cycle of patient populations as well as evaluate the chronic effects of CBD in larger samples of patients with sleep and neuropsychiatric disorders.

    The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. National Center for Biotechnology Information , U.

    Journal List Front Pharmacol v. Published online Apr 5. Guimaraes , 3 Alan Eckeli , 1, 2 Ana C. Crippa , 4 Antonio W.

    Zuardi , 1, 2 Jose D. Souza , 1, 2 Jaime E. Author information Article notes Copyright and License information Disclaimer. This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology. Received Nov 6; Accepted Mar The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.

    No use, distribution or reproduction is permitted which does not comply with these terms. Abstract Cannabidiol CBD is a component of Cannabis sativa that has a broad spectrum of potential therapeutic effects in neuropsychiatric and other disorders. Introduction Cannabidiol CBD , one of the major compounds of Cannabis sativa , has been shown to have several therapeutic effects including antipsychotic Zuardi et al. Open in a separate window.

    Instruments The following instruments were used: Polysomnography The apparatus used for the polysomnography exams consisted of different devices including electroencephalogram with the international 10—20 system to rule out the occurrence of epileptic seizures , electrooculogram, electromyogram of chin muscles and upper and lower limbs, nasal pressure cannula, oral thermistor, thoracic and abdominal respiratory inductive plethysmography straps, pulse oximetry, electrocardiogram, and snoring and body position sensors.

    Novel antiepileptic compounds with new mechanisms of action, fewer side effects, and better safety and tolerability profiles have been approved over the last years. Modern neurosurgery techniques are an option for these patients, but drug-resistant epileptic patients often fail to meet the clinical criteria for surgery, and a significant number of operated patients do not achieve full seizure remission.

    The medicinal effects of cannabis in epilepsy have been known for centuries and, nowadays, the anticonvulsant properties of its components have received increasing attention Leo et al. The discovery of endocannabinoids and cannabinoid receptors in the brain has renewed the interest in the potential of cannabinoid compounds to treat seizures dos Santos et al.

    The Cannabis sativa plant contains more than compounds, of which are known as phytocannabinoids. Anecdotal reports suggest that cannabis has an anti-seizure potential and could thus be used to treat subjects with epilepsy. Cannabis is currently approved for the treatment of epilepsy in several states of the United States and in Israel and Canada Paolino et al. However, the lack of controlled studies and the fact that cannabis contains many other substances including other cannabinoids at different concentrations have hindered definitive conclusions.

    Moreover, reports suggest that crude cannabis may have no efficacy and may even exacerbate epileptic seizures Tofighi and Lee, ; Hamerle et al. Animal studies and preliminary clinical trials have shown significant improvements in children with treatment-resistant epilepsy treated with CBD-enriched extracts Rosenberg et al.

    The general press and social media have raised attention to these products in countries such as the United States, United Kingdom, and Brazil. This led to the development of a wide range of cannabis-derived products for oral use with no regulation, quality assurance, or accurate content labeling Vandrey et al. Led by despair, many families have resorted to these products usually commercialized as dietary supplements in an attempt to control the seizures of their children Vandrey et al.

    The potential chronic medical use of non-purified CBD extracts raises important concerns, particularly in children and adolescents with a developing brain. First, the long-term use of drugs containing THC may have adverse and long-lasting harmful effects such as the onset of chronic psychiatric disorders, addiction, cognitive impairment, and changes in brain function that can have an impact on educational, professional, and social achievements Volkow et al.

    Second, the use of edible products makes it difficult to titrate doses, which can lead to over- or under-dosing and implies the risk of drug-interactions with other medicines. A year-old girl was diagnosed with refractory epilepsy and left frontal dysplasia at 5 months of age.

    Prior to cannabinoid treatment she presented about three complex focal seizures. Treatment with phenytoin, topiramate, carbamazepine, levetiracetam, lamotrigine, primidone, and clobazam for appropriate periods and at adequate doses did not lead to seizure remission.

    Her histological diagnosis after surgery was focal cortical dysplasia type 1b. After 4 months, seizures reappeared every day in the morning, despite treatment with topiramate, valproate, and clobazam. An analysis of the extract which remained the same during the initial treatment detected 4. The arrows show a mildly hypoplastic frontal lobe with focal T2 signal hyperintensity on the cortico-subcortical transition A—C and the resected region D.

    A 7-year-old boy had a diagnosis of refractory epilepsy due to SCN1A mutations associated with Dravet syndrome. Prior to treatment with cannabinoids, he presented daily complex, focal, myoclonic, tonic, and absence seizures. In addition to severe myoclonic epilepsy, the child also presented behavioral and developmental delays, hyperactivity and impulsiveness, and autistic-like behaviors.

    The boy underwent anticonvulsant treatment for appropriate periods and with adequate doses, failing to respond to several drugs including stiripentol, valproic acid, oxcarbazepine, topiramate, levetiracetam, phenytoin, phenobarbital, and sulthiame.

    After 3 months, however, the patient started to present ataxia, reduced attention, irritability, aggressiveness, and seizure worsening. An analysis of the cannabis extract detected 3. This dose led to complete improvement of all intoxication symptoms after 1 week of treatment as indicated by clinical evaluation, EEG improvements, and complete seizure remission after 3 weeks of the new treatment.

    The child also had a clear improvement in most of the autistic-like symptoms over the course of 6 months, including poor communication vocabulary and spelling , poor social interaction, and repetitive and limited behavior, which allowed the boy to start school and get involved in sports activities like swimming.

    Follow up assessments at 1 year Case A and 1 year and 10 months Case B showed remission of seizures and clear progressive improvement of the remaining general symptoms with the use of pure CBD. The other medications remained stable before and during the time of transition from the cannabinoid extract to the purified CBD in both cases. Likewise, there were no changes in the dose or frequency of administration of the purified CBD oil.

    Molecular Genetics and Metabolism Print , v. Identification of 30 novel mutations among Latin American patients. Journal of the American College of Nutrition Print , v. Civallero G ; Civallero, G. Extended use of a selective inhibitor of acid lipase for the diagnosis of Wolman disease and cholesteryl ester storage disease. Gene Amsterdam , v. Niemann-Pick disease type C: Arquivos de Neuro-Psiquiatria Impresso , v.

    The natural history of MPS I:

    Publicações ano 2014

    Abstract: Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with. . Ana C.S. Crippa - Serviço de Neurologia / Hospital de Clínicas da UFPR - Rua General Fabio Agertt, Ana C.S. Crippa, Paulo J. Lorenzoni, Rosana H. Scola. Menkes' disease: case report. Doença de Menkes: relato de caso. Fabio Agertt; Ana C.S. Crippa; Paulo J. Lorenzoni; Rosana H. Scola; Isac Bruck; Luciano de.




    Abstract: Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with. .


    Ana C.S. Crippa - Serviço de Neurologia / Hospital de Clínicas da UFPR - Rua General Fabio Agertt, Ana C.S. Crippa, Paulo J. Lorenzoni, Rosana H. Scola.


    Menkes' disease: case report. Doença de Menkes: relato de caso. Fabio Agertt; Ana C.S. Crippa; Paulo J. Lorenzoni; Rosana H. Scola; Isac Bruck; Luciano de.


    Doença de Niemann-Pick tipo C: série de casos de pacientes brasileiros. Paulo José Lorenzoni. Elaine Cardoso. Ana C. S. Crippa. Charles Marques Lourenço.


    Crippa, José Alexandre, Crippa, Ana Chrystina S, Hallak, Jaime Eduardo, Martin- Santos, Rocio, Zuardi, Antonio Waldo, Crippa, José A. S., Crippa, Ana C. S.


    Publications by authors named "Jose A Crippa". Are you .. Authors: José A S Crippa Ana C S Crippa Jaime E C Hallak Rocio Martín-Santos Antonio W Zuardi.

    Add Comment